Gregory J. Riely, MD, PhD
Posted: Sunday, January 28, 2018
Roy S. Herbst, MD, PhD, of the Yale School of Medicine, discusses effective combination therapies and why some tumors are resistant to immunotherapy.
JNCCN Spotlights
View More
Resources
For your Patients